Investors of Hims & Hers Health May Join Major Securities Fraud Class Action
Hims & Hers Securities Fraud Class Action
Introduction
Investors in Hims & Hers Health, Inc. (NYSE: HIMS) have a significant opportunity to join a class action lawsuit regarding potential securities fraud. The Rosen Law Firm has made a call to action for individuals who purchased common stock during a specified period in 2025.
This article aims to provide a comprehensive overview of the opportunity available for investors impacted during the class period, which spans from April 29, 2025, to June 23, 2025. If you bought the stock during this time frame, you may be eligible for compensation under the class action settlement.
Key Details of the Class Action
The legal deadline for individuals wishing to serve as lead plaintiff in this class action is August 25, 2025. Those interested should familiarize themselves with the next steps to ensure they are appropriately represented.
The class action has already been initiated, so affected investors are encouraged to reach out via the provided channels for further information or to express their intent to participate.
To become part of this significant legal movement, investors can visit Rosen Legal or call attorney Phillip Kim at 866-767-3653. Email inquiries can be directed to [email protected]
Basis of the Lawsuit
The lawsuit revolves around allegations that misleading statements concerning the relationship between Hims & Hers and Novo Nordisk A/S, a key pharmaceutical partner, may have harmed investors' interests. Specifically, it claims that:
- - The partnership was portrayed as a long-term collaboration to ensure access to the weight-loss drug Wegovy.
- - Misleading positive statements were made about Hims’ offerings of compounded semaglutide products under a specific
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.